CurrentUnitedHealthcarePolicy N/A

Prior Authorization — Tobacco Cessation Pharmacotherapy (varenicline, Nicotrol NS, Nicotrol Inhaler)

Defines UnitedHealthcare prior authorization and coverage rules for tobacco cessation medications (varenicline, Nicotrol NS, Nicotrol inhaler) including eligibility, required prior therapies, duration limits, and zero dollar cost-share provisions; applies to members under UnitedHealthcare pharmacy programs.

Policy Summary

PayerUnitedHealthcare

PolicyPrior Authorization — Tobacco Cessation Pharmacotherapy (varenicline, Nicotrol NS, Nicotrol Inhaler)

Policy CodePolicy N/A

Change TypeDuration limit addedstate bypasses clarifiedbupropion guidance revised

Effective Date6/1/2025

Next Review DateN/A

Key ActionObtain prior authorization and document prior NRT and bupropion failure/contraindication before approving varenicline or Nicotrol products.

SourceLink

POLICY UPDATE CHANGES

Treatment duration limited to two 3-month cycles of tobacco cessation therapy per 12-month period.

Revised criteria to allow coverage if currently using bupropion for an indication other than tobacco cessation (historical change noted).

Added state-specific prior authorization bypasses (CA, CO, IL, NY, WV) and age variation for Oregon.

Effective date listed as 6/1/2025.

2maximum 3-month cycles allowed per 12 months

3 monthsauthorization duration per cycle

0member copay for authorized therapy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Varenicline (Chantix) - Initial Approval

Varenicline will be approved when ALL of the following are met:

Age: Patient is 18 years of age or older (age 15+ for Oregon-sitused plans as noted elsewhere)>=18 years (>=15 for OR)

chunk 2,5

Indication: Treatment is requested for tobacco cessation

chunk 3

Prior NRT failure: History of failure, contraindication, or intolerance to OTC nicotine replacement patches, lozenge/mini-lozenge, and gum

chunk 3

Bupropion trial: History of failure, contraindication, or intolerance to bupropion

chunk 3

Quantity/duration limit: Treatment duration has not exceeded a total of two (3-month) cycles of Tobacco Cessation Therapy per 12-month period<=2 cycles per 12 months

chunk 3

Nicotrol NS / Nicotrol Inhaler - Initial Approval

Nicotrol NS or Nicotrol Inhaler will be approved when ALL of the following are met:

Age: Patient is 18 years of age or older (age 15+ for Oregon-sitused plans as noted elsewhere)>=18 years (>=15 for OR)

chunk 4,5

Indication: Treatment is requested for tobacco cessation

chunk 5

Prior NRT failure: History of failure, contraindication, or intolerance to OTC nicotine replacement patches, lozenge/mini-lozenge, and gum

chunk 5

Bupropion trial:

Program exceptions and operational rules

Program-level rules and exceptions:

State bypass: Review not required for plans sitused in the states of California, Colorado, Illinois, New York, or West Virginia

chunk 5

Automated approval: UnitedHealthcare may approve initial and reauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic

chunk 6

Pharmacist review required for more than 2 cycles per 12-month period>2 cycles per 12 months

chunk 5

Historical reference: the policy language has been updated to remove mention of Zyban because that product has become obsolete and is no longer referenced in current program criteria or prior authorization rules.

Treatment beyond the program limit is not routinely authorized. Authorization is issued for 3 months per cycle with a maximum of two (2) cycles per 12-month period. Requests that would exceed this limit are subject to additional review and require pharmacist review when more than two cycles are requested. Lack of required prior therapies or exceeding the two-cycle limit may render a request not medically necessary.

Coding & Limits

inv-06: Treatment duration limit

Treatment duration limitMaximum 2 cycles (each cycle = 3 months) per 12‑month period

Authorization duration per cycle3 months per authorization (one cycle = 3 months)

Maximum authorized months per 12 monthsUp to 6 months total (2 cycles x 3 months)

Cost-shareAuthorization issued with zero copay and deductible bypass for authorized cycles

Exception handlingTherapy beyond two 3‑month cycles in 12 months requires pharmacist review and is not routinely authorized

Provider Actions & Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization required for varenicline (Chantix/generic) and Nicotrol products (nasal spray and inhaler) except where state-specific review/bypass applies.

Approval issued for 3 months (zero copay with deductible bypass) per cycle; maximum 2 cycles (each 3 months) per 12-month period.
Plans sitused in CA, CO, IL, NY, and WV: review not required for Nicotrol products.
Age exceptions: standard minimum age 18; Oregon plans: minimum age 15.

Step Therapy

Required Prior Therapies

Requires documented history of failure, contraindication, or intolerance to first-line nicotine replacement therapies and to bupropion before approval.

Must document failure/contraindication/intolerance to: nicotine replacement patch (OTC, e.g., Nicoderm CQ), nicotine lozenge/mini-lozenge (OTC, e.g., Nicorette lozenge), and nicotine gum (OTC, e.g., Nicorette gum).

Background

Tobacco cessation therapies are most effective when patients are motivated and receive counseling and supportive services alongside pharmacotherapy. This program provides coverage for tobacco cessation medications dispensed through the pharmacy benefit and is designed to meet Health Care Reform requirements for zero dollar cost-share when authorization criteria are met. The policy pairs medication coverage with operational rules — including age thresholds, required prior trials of over-the-counter nicotine replacement therapies and bupropion, and limits on treatment duration — to target therapy to members seeking cessation support.

Definitions

inv-12: Cycle

TermOne cycle

UsageUsed as the label/term for the policy's treatment period unit

ContextReferenced when counting maximum allowable therapy within 12 months

inv-13: Cycle definition / pharmacist review

Operational definitionOne cycle is defined as a 3‑month authorization period

Pharmacist review thresholdPharmacist review is required for requests exceeding 2 cycles per 12‑month period

Partial fills rule

Initial Therapy Criteria

Initial therapy criteria

Initial authorization criteria

Age: Patient meets minimum age requirement>=18 years (>=15 for OR)

chunk 2,4,5

Indication: Treatment requested for tobacco cessation

chunk 3,5

Prior NRT failure: History of failure, contraindication, or intolerance to OTC NRT patches, lozenge/mini-lozenge, and gum

chunk 3,5

Continuation / Reauthorization Criteria

Continuation therapy

Continuation / reauthorization rules

Reauthorization duration: Authorization issued for 3 months per cycle with maximum of two cycles per 12-month period3 months per authorization; <=2 cycles/12 months

chunk 3,5

Step Therapy Requirements

Step	Required prior therapy (must be documented)
1	Documented history of failure, contraindication, or intolerance to nicotine replacement patches (OTC, e.g., Nicoderm CQ)
2	Documented history of failure, contraindication, or intolerance to nicotine lozenge or mini‑lozenge (OTC, e.g., Nicorette lozenge)
3	Documented history of failure, contraindication, or intolerance to nicotine gum (OTC, e.g., Nicorette gum)
4	Documented history of failure, contraindication, or intolerance to bupropion

Quantity Limits

inv-17: All tobacco cessation medications covered in this policy

Quantity limit per authorization3 months per authorization

Covered productsAll tobacco cessation medications included in this policy (varenicline, Nicotrol NS, Nicotrol Inhaler)

Reauthorization limitMaximum of two 3‑month authorizations per 12‑month period

Cost-shareAuthorized supplies are issued with zero copay and deductible bypass

Site of Care

Billing Rule

Pharmacy dispensed; zero dollar cost-share

Coverage is provided as pharmacy-dispensed outpatient medications and the program is designed to meet Health Care Reform requirements to provide tobacco cessation coverage with zero dollar member cost share for authorized therapy.

Pharmacy-dispensed outpatient setting
Authorized therapy issued with zero copay and deductible bypass for 3 months per authorization